Ísrael - hebreska - Ministry of Health

pfizer pharmaceuticals israel ltd - dacomitinib as monohydrate - טבליות מצופות פילם - dacomitinib as monohydrate 30 mg - dacomitinib

Ísrael - hebreska - Ministry of Health

pfizer pharmaceuticals israel ltd - dacomitinib as monohydrate - טבליות מצופות פילם - dacomitinib as monohydrate 45 mg - dacomitinib

Ísrael - hebreska - Ministry of Health

pfizer pharmaceuticals israel ltd - palbociclib - טבליות מצופות פילם - palbociclib 100 mg - palbociclib

Ísrael - hebreska - Ministry of Health

pfizer pharmaceuticals israel ltd - palbociclib - טבליות מצופות פילם - palbociclib 125 mg - palbociclib

Ísrael - hebreska - Ministry of Health

pfizer pharmaceuticals israel ltd - palbociclib - טבליות מצופות פילם - palbociclib 75 mg - palbociclib

Ísrael - hebreska - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.